ロード中...
High-Dose Infliximab Therapy in Crohn’s Disease: Clinical Experience, Safety, and Efficacy
BACKGROUND: Inadequate response to infliximab [IFX] therapy in Crohn’s disease [CD] may necessitate dose intensification. We evaluated safety and efficacy of high-dose IFX [HD IFX] [greater than 10mg/kg every 8 weeks] in CD and characterized predictors of response to HD IFX intensification. METHODS:...
保存先:
| 出版年: | J Crohns Colitis |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6497242/ https://ncbi.nlm.nih.gov/pubmed/25540149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jju026 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|